Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia
Dieter Naber, Karina Hansen, Carlos Forray, Ross A Baker, Christophe Sapin, Maud Beillat, Timothy Peters-Strickland, Anna-Greta Nylander, Peter Hertel, Henrik Steen Andersen, Anna Eramo, Jean-Yves Loze, Steven G Potkin, Dieter Naber, Karina Hansen, Carlos Forray, Ross A Baker, Christophe Sapin, Maud Beillat, Timothy Peters-Strickland, Anna-Greta Nylander, Peter Hertel, Henrik Steen Andersen, Anna Eramo, Jean-Yves Loze, Steven G Potkin
Abstract
Objective: To directly compare aripiprazole once-monthly 400mg (AOM 400) and paliperidone palmitate once-monthly (PP) on the Heinrichs-Carpenter Quality-of-Life Scale (QLS), a validated health-related quality of life and functioning measure in schizophrenia.
Method: This 28-week, randomized, non-inferiority, open-label, rater-blinded, head-to-head study (QUALIFY) of AOM 400 and PP in adult patients (18-60 years) comprised oral conversion, initiation of AOM 400 or PP treatment, and continuation with intramuscular injections every 4weeks. The primary endpoint assessed non-inferiority and superiority on QLS total score analyzed using a mixed model for repeated measurements.
Results: Of 295 randomized patients, 100/148 (67.6%) of AOM 400 and 83/147 (56.5%) of PP patients completed 28weeks of treatment. A statistically significant least squares mean difference in change from baseline to week 28 on QLS total score (4.67 [95%CI: 0.32;9.02], p=0.036) confirmed non-inferiority and established superiority of AOM 400 vs PP. There were also significant improvements in Clinical Global Impression - Severity scale and the Investigator's Assessment Questionnaire for AOM 400 vs PP, and pre-defined sub-group analyses revealed a consistent pattern of significance favoring AOM 400 in patients ≤35years. Common treatment-emergent adverse events in the treatment continuation phase were more frequent with PP vs AOM 400, and adverse events were the most frequent reason for discontinuation (27/137 [19.7%] for PP and 16/144 [11.1%] for AOM 400). All-cause discontinuation was numerically lower with AOM 400.
Conclusion: Superior improvements on clinician-rated health-related quality of life and a favorable tolerability profile suggest greater overall effectiveness for aripiprazole once-monthly vs paliperidone palmitate. ClinicalTrials.gov identifier:NCT01795547.
Keywords: Antipsychotic treatment; Aripiprazole; Clinical trial; Functioning; Long-acting injectable; QLS.
Copyright © 2015. Published by Elsevier B.V.
Source: PubMed